Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL17F drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL17F ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View IL17F Products |
| Gene Delivery | IL17F Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View IL17F Products |
| Benchmark Ab | Anti-IL17F (Sequence of Bimekizumab) Recombinant positive control. |
View IL17F Products |
| Validator | IL17F siRNA Set For knockdown verification. |
View IL17F Products |
| Related Target A | IL17A Synergistic pathway; forms heterodimers with IL17F. |
View IL17A Products |
| Related Target B | IL23A Upstream regulator of the Th17 pathway. |
View IL23A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity and strictly sequence verified |
| Homodimer vs Heterodimer screening | Recombinant IL17A, IL17F, and IL17A/F heterodimer proteins strictly verified by mass spec |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live IL17F R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL17F therapeutics is intensifying, with major players shifting focus from traditional mono-specific mAbs to dual-targeting modalities (IL17A/IL17F). As first-generation therapies reach the clinic and demonstrate superior efficacy in psoriasis and ankylosing spondylitis, the next wave of R&D is targeting optimal binding kinetics to balance deep inflammatory clearance with manageable fungal infection risks.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Dual Monoclonal Ab | UCB (Bimekizumab) | Psoriasis, Hidradenitis Suppurativa | Neutralization Assay (Need High-purity Antigens) |
| Bispecific Ab | MoonLake Immunotherapeutics | Psoriatic Arthritis, AS | Selectivity Assay (Need IL17A vs IL17F panels) |
| Small Molecule | Dice Therapeutics, Sanofi | Psoriasis (Oral) | Binding Inhibition (Need Sequence-verified targets) |